{"id":39355,"date":"2025-08-14T14:50:34","date_gmt":"2025-08-14T06:50:34","guid":{"rendered":"https:\/\/flcube.com\/?p=39355"},"modified":"2025-08-14T14:50:35","modified_gmt":"2025-08-14T06:50:35","slug":"everest-medicines-velsipity-nda-accepted-for-review-in-taiwan","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39355","title":{"rendered":"Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan"},"content":{"rendered":"\n

China-based Everest Medicines (HKG: 1952<\/a>) announced that the New Drug Application (NDA) for its Velsipity (etrasimod, trade name in Taiwan: \u7dad\u9577\u5be7) has been accepted for review by Taiwan Food and Drug Administration (TFDA). This marks another step in the global regulatory journey for etrasimod, which treats moderate to severe active ulcerative colitis (UC). Previously, the NDA was approved in Macau SAR, Singapore, and Hong Kong SAR, and is under review in South Korea. China’s National Medical Products Administration (NMPA) also accepted the NDA for etrasimod in December 2024, with approval anticipated by the end of the year or early next year.<\/p>\n\n\n\n

About Etrasimod<\/strong>
Etrasimod is a once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator. It effectively promotes intestinal mucosal healing, offers convenient administration, and has a favorable safety profile. The NDA submission is based on the ELEVATE UC Phase III registration studies (ELEVATE UC 52 and ELEVATE UC 12) and the ENLIGHT study (ES101002). These studies showed etrasimod achieved significant and sustained clinical remission and deep endoscopic mucosal healing at weeks 12 and 52. Importantly, all clinical remissions achieved were steroid-free, and the safety profile remained consistent with previous studies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity…<\/p>\n","protected":false},"author":1,"featured_media":39357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1164,38],"class_list":["post-39355","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-1952","tag-market-approval-filings"],"yoast_head":"\nEverest Medicines' Velsipity NDA Accepted for Review in Taiwan - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity (etrasimod, trade name in Taiwan: \u7dad\u9577\u5be7) has been accepted for review by Taiwan Food and Drug Administration (TFDA). This marks another step in the global regulatory journey for etrasimod, which treats moderate to severe active ulcerative colitis (UC). Previously, the NDA was approved in Macau SAR, Singapore, and Hong Kong SAR, and is under review in South Korea. China's National Medical Products Administration (NMPA) also accepted the NDA for etrasimod in December 2024, with approval anticipated by the end of the year or early next year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39355\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines' Velsipity NDA Accepted for Review in Taiwan\" \/>\n<meta property=\"og:description\" content=\"China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity (etrasimod, trade name in Taiwan: \u7dad\u9577\u5be7) has been accepted for review by Taiwan Food and Drug Administration (TFDA). This marks another step in the global regulatory journey for etrasimod, which treats moderate to severe active ulcerative colitis (UC). Previously, the NDA was approved in Macau SAR, Singapore, and Hong Kong SAR, and is under review in South Korea. China's National Medical Products Administration (NMPA) also accepted the NDA for etrasimod in December 2024, with approval anticipated by the end of the year or early next year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39355\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-14T06:50:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-14T06:50:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1409.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan\",\"datePublished\":\"2025-08-14T06:50:34+00:00\",\"dateModified\":\"2025-08-14T06:50:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1409.webp\",\"keywords\":[\"HKG: 1952\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39355#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39355\",\"name\":\"Everest Medicines' Velsipity NDA Accepted for Review in Taiwan - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1409.webp\",\"datePublished\":\"2025-08-14T06:50:34+00:00\",\"dateModified\":\"2025-08-14T06:50:35+00:00\",\"description\":\"China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity (etrasimod, trade name in Taiwan: \u7dad\u9577\u5be7) has been accepted for review by Taiwan Food and Drug Administration (TFDA). This marks another step in the global regulatory journey for etrasimod, which treats moderate to severe active ulcerative colitis (UC). Previously, the NDA was approved in Macau SAR, Singapore, and Hong Kong SAR, and is under review in South Korea. China's National Medical Products Administration (NMPA) also accepted the NDA for etrasimod in December 2024, with approval anticipated by the end of the year or early next year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39355\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1409.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1409.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest Medicines' Velsipity NDA Accepted for Review in Taiwan\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39355#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines' Velsipity NDA Accepted for Review in Taiwan - Insight, China's Pharmaceutical Industry","description":"China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity (etrasimod, trade name in Taiwan: \u7dad\u9577\u5be7) has been accepted for review by Taiwan Food and Drug Administration (TFDA). This marks another step in the global regulatory journey for etrasimod, which treats moderate to severe active ulcerative colitis (UC). Previously, the NDA was approved in Macau SAR, Singapore, and Hong Kong SAR, and is under review in South Korea. China's National Medical Products Administration (NMPA) also accepted the NDA for etrasimod in December 2024, with approval anticipated by the end of the year or early next year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39355","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines' Velsipity NDA Accepted for Review in Taiwan","og_description":"China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity (etrasimod, trade name in Taiwan: \u7dad\u9577\u5be7) has been accepted for review by Taiwan Food and Drug Administration (TFDA). This marks another step in the global regulatory journey for etrasimod, which treats moderate to severe active ulcerative colitis (UC). Previously, the NDA was approved in Macau SAR, Singapore, and Hong Kong SAR, and is under review in South Korea. China's National Medical Products Administration (NMPA) also accepted the NDA for etrasimod in December 2024, with approval anticipated by the end of the year or early next year.","og_url":"https:\/\/flcube.com\/?p=39355","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-14T06:50:34+00:00","article_modified_time":"2025-08-14T06:50:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1409.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39355#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39355"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan","datePublished":"2025-08-14T06:50:34+00:00","dateModified":"2025-08-14T06:50:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39355"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39355#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1409.webp","keywords":["HKG: 1952","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39355#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39355","url":"https:\/\/flcube.com\/?p=39355","name":"Everest Medicines' Velsipity NDA Accepted for Review in Taiwan - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39355#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39355#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1409.webp","datePublished":"2025-08-14T06:50:34+00:00","dateModified":"2025-08-14T06:50:35+00:00","description":"China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity (etrasimod, trade name in Taiwan: \u7dad\u9577\u5be7) has been accepted for review by Taiwan Food and Drug Administration (TFDA). This marks another step in the global regulatory journey for etrasimod, which treats moderate to severe active ulcerative colitis (UC). Previously, the NDA was approved in Macau SAR, Singapore, and Hong Kong SAR, and is under review in South Korea. China's National Medical Products Administration (NMPA) also accepted the NDA for etrasimod in December 2024, with approval anticipated by the end of the year or early next year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39355#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39355"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39355#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1409.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1409.webp","width":1080,"height":608,"caption":"Everest Medicines' Velsipity NDA Accepted for Review in Taiwan"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39355#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1409.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39355"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39355\/revisions"}],"predecessor-version":[{"id":39358,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39355\/revisions\/39358"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39357"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}